Adenovirus vaccination against neu oncogene exerts long-term protection from tumorigenesis in BALB/neuT transgenic mice

International Journal of Cancer

Volumn 120, Issue 3, 2007, Pages 574-584

  Gallo, Pasquale ^a   Dharmapuri, Sridhar ^a   Nuzzo, Maurizio ^a   Maldini, Daniele ^a   Cipriani, Barbara ^a   Forni, Guido ^b   Monaci, Paolo ^a  

^a IRBMP Angeletti   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; CD8 ANTIGEN; COMPLEMENTARY DNA; GAMMA INTERFERON; PLASMID DNA; PROTEIN P185;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY TITER; ARTICLE; CANCER IMMUNIZATION; CANCER INHIBITION; CARCINOGENESIS; CELLULAR IMMUNITY; CONTROLLED STUDY; DNA IMMUNIZATION; DNA SEQUENCE; ELECTROSTIMULATION; FEMALE; HUMAN; HUMORAL IMMUNITY; HYPERPLASIA; IMMUNE RESPONSE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; ONCOGENE NEU; PRIORITY JOURNAL; PROTEIN EXPRESSION; SEQUENCE ANALYSIS; SPLEEN CELL; TH1 CELL; TRANSGENIC MOUSE; VIRUS PARTICLE;

ADENOVIRIDAE; AMINO ACID SEQUENCE; ANIMALS; CELL LINE; CELL LINE, TUMOR; CODON; EPITOPES, T-LYMPHOCYTE; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC VECTORS; HUMANS; INJECTIONS, INTRAMUSCULAR; MAMMARY GLANDS, ANIMAL; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, INBRED BALB C; MICE, TRANSGENIC; MOLECULAR SEQUENCE DATA; NIH 3T3 CELLS; PROLIFERATING CELL NUCLEAR ANTIGEN; RATS; RECEPTOR, ERBB-2; TIME FACTORS; VACCINATION;

EID: 33845705855     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.22274     Document Type: Article

References (35)

1. Simons JW, Jaffee EM, Weber CE, Levitsky HI, Nelson WG, Carducci MA, Lazenby AJ, Cohen LK, Finn CC, Clift SM, Hauda KM, Beck LA, et al. Bioactivity of autologous irradiated renal cell carcinoma vaccines generated by ex vivo granulocyte-macrophage colony-stimulating factor gene transfer. Cancer Res 1997;57:1537-46.
2. Dranoff G. GM-CSF-secreting melanoma vaccines. Oncogene 2003;22:3188-92.
3. Salgia R, Lynch T, Skarin A, Lucca J, Lynch C, Jung K, Hodi FS, Jaklitsch M, Mentzer S, Swanson S, Lukanich J, Bueno R, et al. Vaccination with irradiated autologous tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor augments antitumor immunity in some patients with metastatic non-small-cell lung carcinoma. J Clin Oncol 2003;21:624-30.
4. Simons JW, Mikhak B, Chang JF, DeMarzo AM, Carducci MA, Lim M, Weber CE, Baccala AA, Goemann MA, Clift SM, Ando DG, Levitsky HI, et al. Induction of immunity to prostate cancer antigens: results of a clinical trial of vaccination with irradiated auiologous prostate tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer. Cancer Res 1999;59:5160-8.
5. Soiffer R, Hodi FS, Haluska F, Jung K, Gillessen S, Singer S, Tanabe K, Duda R, Mentzer S, Jaklitsch M, Bueno R, Clift S, et al. Vaccination with irradiated autologous melanoma cells engineered to secrete granulocyte- macrophage colony-stimulating factor by adenoviral-mediated gene transfer augments antitumor immunity in patients with metastatic melanoma. J Clin Oncol 2003;21:3343-50.
6. Nemunaitis J. Granulocyte-macrophage colony-stimulating factor gene-transfected autologous tumor cell vaccine: focus[correction to fcous] on non-small-cell lung cancer. Clin Lung Cancer 2003;5:148-57.
7. Nemunaitis J, Cunningham CC, Vukelja S, Ruxer RL, Adams N, Rich D, Paulson AS, MacEachern JB. Phase I trial of topotecan in combination with gemcitabine in refractory solid tumor patients. Cancer Invest 2004;22:360-7.
8. Lee CT, Wu S, Ciernik IF, Chen H, Nadaf-Rahrov S, Gabrilovich D, Carbone DP. Genetic immunotherapy of established tumors with adenovirus-murine granulocyte-macrophage colony-stimulating factor. Hum Gene Ther 1997;8:187-93.
9. Rizzuto G, Cappelletti M, Maione D, Savino R, Lazzaro D, Costa P, Mathiesen I, Cortese R, Ciliberto G, Laufer R, La Monica N, Fattori E. Efficient and regulated erythropoietin production by naked DNA injection and muscle electroporation. Proc Natl Acad Sci USA 1999;96:6417-22.
10. Lucchini F, Sacco MG, Hu N, Villa A, Brown J, Cesano L, Mangiarini L, Rindi G, Kindl S, Sessa F, Vezzoni P, Clerici L. Early and multifocal tumors in breast, salivary, harderian and epididymal tissues developed in MMTY-Neu transgenic mice. Cancer Lett 1992;64:203-9.
11. Di Carlo E, Diodoro MG, Boggio K, Modesti A, Modesti M, Nanni P, Forni G, Musiani P. Analysis of mammary carcinoma onset and progression in HER-2/neu oncogene transgenic mice reveals a lobular origin. Lab Invest 1999;79:1261-9.
12. Boggio K, Nicoletti G, Di Carlo E, Cavallo F, Landuzzi L, Melani C, Giovarelli M, Rossi I, Nanni P, De Giovanni C, Bouchard P, Wolf S, et al. Interleukin 12-mediated prevention of spontaneous mammary adenocarcinomas in two lines of Her-2/neu transgenic mice. J Exp Med 1998;188:589-96.
13. Gallo P, Dharmapuri S, Nuzzo M, Maldini D, Iezzi M, Cavallo F, Musiani P, Forni G, Monaci P. Xenogeneic immunization in mice using HER2 DNA delivered by an adenoviral vector. Int J Cancer 2005;113:67-77.
14. Graham FL, Smiley J, Russell WC, Nairn R. Characteristics of a human cell line transformed by DNA from human adenovirus type 5. J Gen Virol 1977;36:59-74.
15. Nanni P, Pupa SM, Nicoletti G, De Giovanni C, Landuzzi L, Rossi I, Astolfi A, Ricci C, De Vecchi R, Invemizzi AM, Di Carlo E, Musiani P, et al. p185(neu) protein is required for tumor and anchorage-independent growth, not for cell proliferation of transgenic mammary carcinoma. Int J Cancer 2000;87:186-94.
16. Mahoney KH, Miller BE, Heppner GH. FACS quantitation of leucine aminopeptidase and acid phosphatase on tumor-associated macrophases from metastatic and nonmetastatic mouse mammary tumors. J Leukoc Biol 1985;38:573-85.
17. Piechocki MP, Pilon SA, Wei WZ. Complementary antitumor immunity induced by plasmid DNA encoding secreted and cytoplasmic human ErbB-2. J Immunol 2001;167:3367-74.
18. Rovero S, Amici A, Carlo BD, Bei R, Nanni P, Quaglino E, Porcedda P, Boggio K, Smorlesi A, Lollini PL, Landuzzi L, Colombo MP, et al. DNA vaccination against rat her-2/Neu p185 more effectively inhibits carcinogenesis than transplantable carcinomas in transgenic BALB/c mice. J Immunol 2000;165:5133-42.
19. Montgomery DL, Shiver JW, Leander KR, Perry HC, Friedman A, Martinez D, Ulmer JB, Donnelly JJ, Liu MA. Heterologous and homologous protection attainst influenza A by DNA vaccination: optimization of DNA vectors. DNA Cell Biol 1993;12:777-83.
20. Ishihashi M, Maizel JV, Jr. The polypeptides of adenovirus. V. Young virions, structural intermediate between top components and aged virions. Virology 1974;57:409-24.
21. Miyahira Y, Murata K, Rodriguez D, Rodriguez JR, Esteban M, Rodrigues MM, Zavala F. Quantification of antigen specific CD8+ T cells using an ELISPOT assay. J Immunol Methods 1995;181:45-54.
22. Aste-Amezaga M, Bett AJ, Wang F, Casimiro DR, Antonello JM, Patel DK, Dell EC, Franlin LL, Dougherty NM, Bennett PS, Perry HC, Davics ME, et al. Quantitative adenovirus neutralization assays based on the secreted alkaline phosphatase reporter gene: application in epidemiologic studies and in the design of adenovector vaccines. Hum Gene Ther 2004;15:293-304.
23. Nakumura Y, Gojobori T, Ikemura T. Codon usage tabulated from international DNA sequence databases: status for the year 2000. Nucleic Acids Res 2000;28:292.
24. Ben-Levy R, Paterson HF, Marshall CJ, Yarden Y. A single autophosphorylation site confers oncogenicity to the Neu/ErbB- 2 receptor and enables coupling to the MAP kinase pathway. EMBO J 1994;13:3302-11.
25. Kozak M. An analysis of 5′-noncoding sequences from 699 vertebrate messenger RNAs. Nucleic Acids Res 1987;15:8125-48.
26. Kozak M. At least six nucleotides preceding the AUG initiator codon enhance translation in mammalian cells. J Mol Biol 1987;196:947-50.
27. Dunn T. Morphology of mammary tumors in mice. In: Homburger F, ed. The physiopathology of cancer. New York: Hoeber-Harper, 1959. 38-84.
28. Haas J, Park EC, Seed B. Codon usage limitation in the expression of HIV-1 envelope glycoprotein. Curr Biol 1996;6:315-24.
29. Mennani C, Calvaruso F, Facciabene A, Aurisicchio L, Storto M, Scarselli E, Ciliberto G, La Monica N. Efficient induction of T-cell response to carcinoembryonic antigen by a heterologous prime-boost regimen using DNA and adenovirus vectors carrying a codon usase optimized cDNA. Int J Cancer 2005;117:444-55.
30. Quaglino E, Iezzi M, Mastini C, Amici A, Pericle F, Di Carlo E, Pupa SM, De Giovanni C, Spadaro M, Cureio C, Lollini PL, Musiani P, et al. Electroporated DNA vaccine clears away multifocal mammary carcinomas in her-2/neu transgenic mice. Cancer Res 2004;64:2858-64.
31. MacGregor RR, Boyer JD, Ugen KE, Lacy KE, Gluckman SJ, Bagarazzi ML, Chattergoon MA, Baine Y, Higgins TJ, Ciccarelli RB, Coney LR, Ginsberg RS, et al. First human trial of a DNA-based vaccine for treatment of human immunodeficiency virus type 1 infection: safety and host response. J Infect Dis 1998;178:92-100.
32. Casimiro DR, Chen L, Fu TM, Evans RK, Caulfield MJ, Davies ME, Tang A, Chen M, Huang L, Harris V, Freed DC, Wilson KA, et al. Comparative immunogenicity in rhesus monkeys of DNA plasmid, recombinant vaccinia virus, and replication-defective adenovirus vectors expressing a human immunodeficiency virus type I gag gene. J Virol 2003;77:6305-13.
33. Matsui M, Moriya O, Akatsuka T. Enhanced induction of hepatitis C virus-specific cytotoxic T lymphocytes and protective efficacy in mice by DNA vaccination followed by adenovirus boosting in combination with the interleukin-12 expression plasmid. Vaccine 2003;21:1629-39.
34. Boggio K, Di Carlo E, Rovero S, Cavallo F, Quaglino E, Lollini PL, Nanni P, Nicoletti G, Wolf S, Musiani P, Forni G. Ability of systemic interleukin-12 to hamper progressive stages of mammary carcinogenesis in HER2/neu transgenic mice. Cancer Res 2000;60:359-64.
35. Park JM, Terabe M, Sakai Y, Munasinghe J, Forni G, Morris JC, Berzofsky JA. Early role of CD4+ Th1 cells and antibodies in HER-2 adenovirus vaccine protection against autochthonous mammary carcinomas. J Immunol 2005;174:4228-36.